Monitoring circulating gammadelta T cells in cancer patients to optimize gammadelta T cell-based immunotherapy
The success of gammadelta (gd) T cell-based immunotherapy, where the cytotoxic activity of circulating gd T lymphocytes is activated by nitrogen-containing bisphosphonates (n-BP), or possibly by bispecific antibodies or the combination of both, requires a profound knowledge of patients´ gd T cells....
Main Authors: | Hans-Heinrich eOberg, Christian eKellner, Matthias ePeipp, Susanne eSebens, Sabine eAdam-Klages, Martin eGramatzki, Dieter eKabelitz, Daniela eWesch |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2014-12-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fimmu.2014.00643/full |
Similar Items
-
Recent advances in gamma/delta T cell biology: new ligands, new functions, and new translational perspectives
by: Dieter eKabelitz, et al.
Published: (2015-07-01) -
Regulatory Interactions Between Neutrophils, Tumor Cells and T Cells
by: Hans-Heinrich Oberg, et al.
Published: (2019-07-01) -
Obesity and cancer: the gammadelta T cell link
by: Ilan Bank
Published: (2022-05-01) -
Potential use of [gammadelta] T cell-based vaccines in cancer immunotherapy
by: Mohd Wajid A. Khan, et al.
Published: (2014-10-01) -
Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells
by: Hans H. Oberg, et al.
Published: (2018-04-01)